Tucusituzumab: Difference between revisions
m Protected "Tucusituzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
Line 20: | Line 20: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 26: | Line 26: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 17:09, 20 August 2012
WikiDoc Resources for Tucusituzumab |
Articles |
---|
Most recent articles on Tucusituzumab Most cited articles on Tucusituzumab |
Media |
Powerpoint slides on Tucusituzumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Tucusituzumab at Clinical Trials.gov Trial results on Tucusituzumab Clinical Trials on Tucusituzumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Tucusituzumab NICE Guidance on Tucusituzumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Tucusituzumab Discussion groups on Tucusituzumab Patient Handouts on Tucusituzumab Directions to Hospitals Treating Tucusituzumab Risk calculators and risk factors for Tucusituzumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Tucusituzumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Tucusituzumab is a humanized monoclonal antibody used to treat cancers of the epithelial origin. It binds to interleukin-2.